Advaxis, Inc. (NASDAQ: ADXS) is gaining momentum as the stock continues to move higher in the pre-market session on Wednesday.
ADDX stock is up by a whopping 32% to $0.64 in the pre-market session. The stock was up 14.50% on Tuesday’s trading session. Yesterday’s total volume stood at 15.92 million shares, well above its average volume of 6.34 million. The stock moved within a wide range of $0.4245 – 0.4920.
ADXS Recent News
April 28, 2021 – Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- ADXS announced that it will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021.
- Title: A phase 1 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.
- Session Type: Poster Session Abstract Number: 2616 Date and Time: June 4, 2021, 9:00 AM (EDT).
|SHARES OUTSTANDING||137.96 M|
|SHARE FLOAT (%)||133.29 M (96.62%)|
|% HELD BY INSTITUTIONS||7.79|
Recent Stock Performance
|+/- EMA(20)||0.47 (+4.26%)|
|+/- SMA(50)||0.62 (-20.97%)|
|+/- SMA(200)||0.55 (-10.91%)|
|CCI20||20.1997||Neutral||Chaikin Money Flow||-0.0888||Sell|
|MACD||-0.0608||Sell||Money Flow Index||36.0240||Sell|
|STOCH (14,3)||68.9756||Buy||STOCH RSI||1.0000||OverBought|